Prevention & care

Acromegaly: growth hormone, IGF-1, diagnosis, complications, treatment goals, and newer oral-treatment evidence

10 sources · Latest source check 2026-10-08 UTC

On this page

Acromegaly involves prolonged excess growth hormone in adults, causing tissue enlargement and metabolic effects. Usually pituitary-related, it can develop gradually. It is a defined endocrine disease, not a general explanation for fatigue.[1]

GH and IGF-1 are linked, but are not the same measurement

The Endocrine Society explains that pituitary growth hormone stimulates production of insulin-like growth factor 1, largely in the liver. GH participates in growth and metabolism; IGF-1 reflects part of its downstream action. The gland’s secretion and the resulting tissue signal are different parts of the pathway.[2]

Gigantism concerns excess before growth plates close

NIDDK describes gigantism when excess GH begins before growth plates close, allowing excessive height growth. Adult excess instead enlarges bone, cartilage and soft tissues. Growth stage changes the effects.[1]

Slow changes can make the condition difficult to recognize

The NHS describes increasing hand, foot, facial or tongue size, sweating, joint symptoms, altered voice and hand numbness. Sleep, menstrual or sexual symptoms can accompany them. Comparing older photographs can help document change during evaluation; appearance or shoe size alone cannot confirm the diagnosis.[3]

A pituitary cause can affect more than growth-hormone production

Most cases involve a GH-producing pituitary adenoma; rare tumors elsewhere produce GH or stimulate it through GHRH. Biochemical assessment and locating the source answer different questions. Pituitary growths can also cause pressure effects.[1]

The Society separates excess-GH effects from hormone deficiencies and tumor-volume effects. Compression can affect vision or other pituitary functions, while a growth can sometimes secrete more than one hormone. Headache, sexual changes and tiredness therefore need a clinical explanation rather than automatic attribution to one hormone.[2]

Age reference ranges and validated assays matter

The consensus published online in November 2023 and in the 2024 journal issue emphasizes age-adjusted IGF-1, typical clinical findings and validated assays. Equivocal results may need repeat measurement with the same assay and sometimes oral glucose testing. A random GH number is not a stand-alone diagnostic verdict.[4]

GH varies during the day. A supervised oral glucose test assesses appropriate GH suppression after the challenge. Drinking sugar water at home cannot diagnose or exclude pituitary disease.[1]

Biochemical remission is one dimension of follow-up

The diagnosis consensus calls for interpreting biochemical findings alongside symptoms, complications and residual or recurrent mass on imaging. Referral to a multidisciplinary pituitary center is considered for uncertain findings or inadequate response. “Hormones controlled,” “no visible residual growth” and “all symptoms resolved” describe different outcomes.[4]

Surgery and medicines have distinct roles

The Society describes pituitary surgery as an initial treatment for many tumor-related cases, with medicines or radiation when surgery is unsuitable or control remains incomplete. Radiation can take time to reduce excess. Follow-up includes hormone function, not only whether the operation removed visible tissue.[2]

Medical treatments act at different points

Medical treatments act at different points
Class	Broad purpose
Somatostatin receptor ligands	Reduce GH secretion; some also reduce tumor size.[2]
GH-receptor antagonist	Blocks downstream GH signaling rather than simply suppressing secretion.[1]
Dopamine agonists	Can help some patients; effectiveness is not equivalent across all cases.[2]

The 2026 update addresses ongoing health burdens

The April 2026 consensus considers cardiovascular, respiratory, metabolic, bone, joint, oncological and quality-of-life issues. Forty-three experts met in September 2024; the initial literature search covered March 2018 to March 2024, with later publications included during preparation. Publication date and search cutoff are different.[5]

It explains that skeletal fragility can occur despite normal or elevated DXA bone density. Bone quantity and bone quality are different; fractures and vertebral assessment matter alongside biochemical control. Its recommendations distinguish stronger from discretionary proposals. Exact investigations and intervals require individual assessment rather than copying a universal checklist.[5]

Care also monitors conditions outside the pituitary

The NHS includes checks for diabetes, hypertension, heart disease and bowel polyps, with specialist follow-up after treatment. Sleep and joint problems also matter to daily function. Treating the hormone source and addressing the resulting health burden are complementary tasks, not alternative explanations for the same outcome.[3]

The newer oral medicine has a defined approved population

FDA approved Palsonify on September 25, 2025 for adults after inadequate surgical response or when surgery is unsuitable. This updates NIDDK’s 2020 description of oral somatostatin options as being studied.[7][1]

The FDA trial snapshot summarizes two placebo-controlled trials totaling 169 participants, including a separate 24-week trial and the 36-week switch trial. These populations differ. Approval does not establish benefit for people without acromegaly, a replacement for every surgical decision, or equal certainty across underrepresented subgroups.[8]

The prescribing information describes monitoring needs

The September 2025 US label warns about gallstones and complications, high or low glucose, slow heart rate or conduction abnormalities, thyroid changes, fat malabsorption and vitamin B12 deficiency. Oral administration changes delivery, not the need to assess safety, interactions or whether clinical monitoring is appropriate.[9]

Food and interacting medicines can affect exposure, including acid-suppressing treatment and enzyme-inducing drugs. Preparation and prescription instructions belong to the product-specific care plan. A convenience advantage is different from evidence that a medicine is risk-free or suitable for self-directed hormone optimization.[9]

Evidence & uncertainty

Diagnosis and control require biochemical and clinical context. A 2026 consensus updates complication care; a recent oral-treatment trial studied selected previously controlled adults. Neither a normal hormone result nor a short-term trial establishes that every complication has resolved. Complete comparative and expert appraisal remains unfinished.[4][5]

Selected-source overview · Independent review pending

Published questions

Does acromegaly simply mean unusually tall adult height?

Selected-source overview · Independent review pending. Read the evidence context.

Growth-stage effects differ; adult disease commonly enlarges tissues rather than increasing height.[1]

Evidence behind this answer

Acromegaly
agency condition or prevention explanation · 2020
Selected relevant original official page passages inspected · January 2020: adult/growth-plate distinction, pathway, causes and receptor-antagonist mechanism; dated oral-treatment description identified